syndrome as well as autoimmune or inflammatory disl l orders requiring long term immune suppression such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren syndrome, myasthenia gravis and vasculitides. 4l7 Although the pathology of PCNSL is diffuse large B cell in 95% of the cases, other histologies like Tlcell lymphomas, anaplastic large cell and even indolent hisl l tologies are regularly encountered. 8, 9 Unfortunately no prospective randomized controlled data are available to guide the management of PCNSL and most experience comes from small prospective phase II studies and retl l rospective series. 10l17 Traditionally PCNSL was treated with whole brain radiation therapy (WBRT) with a median overall survival of 16 months. 17 However, a metalanalysis of 1180 patients from 50 series published in 1997 suggested that survival may be better when treated with a combined modality approach including chemotherapy and radiation. 18 Adding to this control l versy has been several reports stating that survival may be equivalent or even better with chemotherapy alone, thus avoiding the longlterm toxicity from whole brain radiotherapy. 19 Important issues that remain unanl l swered are type of chemotherapy, single agent versus combination chemotherapy, dose and technique of ral l diation therapy, and the role if any of monoclonal antil l body therapy, especially in B cell lymphoma.
At our institution, PCNSL was treated with WBRT until 2001 when we changed our guidelines to include chemotherapy and radiation as part of primary manl l agement of PCNSL. We therefore decided to review our results with combined modality therapy.
METHODS
After obtaining approval from our institutional review board, we identified all patients diagnosed and treated with primary central nervous system lymphoma from the Oncology Data Unit at our institution from 1994 to 2004. For inclusion into this analysis, patients older than 18 years of age had to have a confirmed histologic diagnosis of central nervous system lymphoma in the absence of any radiologic evidence of systemic involvel l ment. The patient had to have a followlup of 6 months to be included in this analysis. Patients with any conl l genital or acquired immune deficiency states including HIV or therapeutic immunelsuppression were excludl l ed. Data on age, sex, histology, performance status at diagnosis, location of lesions (deep versus superficial), type of surgery (biopsy versus debulking) and multil l plicity of lesions as well as primary treatment and treatl l ment intent were collected.
Chemotherapy consisted of highldose methotrexate at a dose of 3 g/m 2 at two weekly intervals for a total of 4 cycles. Standard precautions with aggressive prel chemotherapy hydration and alkalization of urine as well as postlchemotherapy rescue with intravenous and oral folinic acid were instituted until serum methotrexl l ate levels became nontoxic according to our laboratory reference ranges.
Radiation therapy was considered to have been del l livered with curative intent if the total dose exceeded 4000 Gy given over at least 4 weeks to the whole brain (180l200 cGy/fraction, 5 fractions per week). The ral l diation was given in two parallel opposed fields using 6l10 MV linear accelerator machine. Radiation given at a total dose lower than 4000 cGy was considered to have been delivered with palliative intent. In combined modality group radiation had to start within 4 weeks of the last cycle of chemotherapy.
The patients underwent MRI scan of the brain at diagnosis as well as CT scans of the chest, abdomen and pelvis and lumbar puncture at diagnosis. A repeat MRI scan to assess response was done after the end of chemotherapy in those who were managed with coml l bined modality therapy. All patients had evaluation of response at the end of all planned treatment with an MRI and were then followed at 3 monthly intervals with a followlup MRI scan as well as clinical evaluation to assess residual neurologic deficit and/or longlterm toxicity from treatment.
All statistics were performed with SPSS software 
RESULTS
We identified 62 patients treated from 1994 to 2004 who fulfilled the criteria for inclusion. There were 34 males and 28 females with an almost equal maleltolfemale ral l tio. Median age was 48.2 years (range 29l76). Sixtylsix percent (n=41) had an ECOG performance status of greater than 2, while 34% had a performance status of 0l2. Fortylsix patients (74%) presented with a solitary lel l sion and 16 (26%) had multiple lesions at presentation. Diffuse large B cell lymphoma (DLBCL) was the predominant histology (n=57, 92%). Other subtypes included peripheral T cell lymphoma in 3 patients (4.8%), follicular lymphoma and immunoblastic lyml l phoma in one patient each (Table 1) .
Treatment consisted of combined modality therapy (CMT) in 16 (26%), radiation therapy with curative intent in 36 patients (58%) and radiation therapy with palliative intent in 10 (16%). To eliminate bias towards CMT we excluded 10 patients treated with palliative intent from further analyses and present the response and survival data on patients treated with CMT and 
DISCUSSION
In this retrospective series, the median OS and EFS for the entire group was 11 and 8 months, respectively. OS was significantly longer (45 months) for the CMT group compared to the radiation therapy group (10.5 months) (P=.033). EFS was similarly prolonged in the CMT group (33.1 months vs. 7.1 months; P=.035). Patients who received RT were older, with poorer performance and with a higher frequency of multifocal disease. These findings were likely responsible for the lower EFS and OS and the loss of significance in the multivariate analyl l sis. Our data for CMT is similar to previous results from both retrospective analyses and prospective trials. 12,15,20l 24 In an Australian phase II trial, patients who received two cycles of highldose methotrexate (1 g/m 2 ) followed by 45 Gy of whole brain external radiation therapy (WBXRT) had an OS of 33 months. 23 Similarly in a Radiation Therapy Oncology Group (RTOG) study, patients who were given more prolonged methotrexatel based chemotherapy and WBXRT (45 Gy) followed by highldose cytarabine had a median OS of 37 months. 15 A retrospective analysis of 357 patients reported in 19 prospective series, reported that patients receiving methotrexate at doses ≥3 g/m 2 had a significantly longer median survival compared with those receiving <3 g/m 2 (P=.04). 25 There was no difference in overall survival (OS) among those receiving single agent chemotherapy and combination chemotherapy (P=.38). Of the 119 complete responders, 70 received immediate RT. A RT dose of ≥40 Gy to the whole brain or tumor bed did not improve OS. The 3lyear OS was similar between the immediate and delayed RT groups. In a multivariate analysis, RT delay had no negative impact on survival. 25 Somewhat similar results were noted in a multicenter study reporting on survival data in 370 patients treated at 23 different centers. 19 Patients treated with radiation therapy alone had the worst twolyear OS (25 percent), whereas those treated with high doses of methotrexate and cytarabine had the best survival (64 percent). The overall survival with combined modality therapy appears to be superior to that in previous reports. This may be because our patient cohort belonged to a more favorable prognostic group based on the International Extranodal Lymphoma Study Group (IESLG) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic criteria. 26, 27 Our patient population consistl l ed predominantly of young patients, with good perforl l mance status. Most of them had undergone debulking surgery and 98.5% of them had solitary lesions. All of these are favorable prognostic features in IESLG and MSKCC prognostic scores for PCNSL.
Unfortunately, no randomized data exist to prove sul l radiation therapy with curative intent (n=52). In this group all histology was DLBCL. Median age was 52 years in the radiation alone group while it was 42 in the CMT group ( 
Response and Survival
Overall response rate (CR+PR) was 74% in the CMT group and 55% in the RT group. The complete remisl l sion rate was 7/16 (44%) and 13/36 (36%) while the partial response rate was 31% (5/16) and 19% (7/36) in the CMT and RT groups, respectively (P=.50 for PR).
One patient in the CMT and 4 in the RT group had progressive disease while 3 and 12 had stable disease in their respective groups (Table 3 ). the recurrence rate was significantly lower in the CMT group compared to the RT group, 19% (3/16) and 50% (18/36), respecl l tively (P=.01). Two patients and one patient in each group, respectively, were not assessed for recurrence. Median TTP was 11.8 months in the CMT group and 4.8 months in the RT group (Table 4) . For the entire group, at a median followlup of 25.7months (SD=19.1 months), the median EFS was 8 months (22.5% and 16.8% at 3 and 5 years, respectively) ( Figure 1 ). Median OS was 11 months (36% and 22% at 3 and 5 years, respectively) ( Figure  2 ). Median EFS was 33.1 months and 7.1 months for CMT and RT, respectively (at 3 years 48.8% and 22.1% and at 5 years 24.4% and 17.7%, respectively; P=.035; HR=0.58 with 95% confidence interval of 0.48l0.93) (Figure 3 ). Median OS was 45 months and 10.5 months for CMT and RT, respectively (at 3 years 57% and 31.6% and at 5 years 38% and 20.3%, respecl l tively; P=.033; HR=0.64 with 95% confidence interl l val of 0.52l0.98) (Figure 4 ).
In the univariate analysis of the prognostic impact of different factors (primary treatment, age, PS, type of surgery, multiplicity of lesions and radiation dose) we found primary treatment (CMT vs. RT) and age (<50 or >50 years) ( Figures 5, 6) to have a significant influl l ence on survival (Table 5 ). Age (as a constant factor) was the only significant factor influencing survival on multivariate analyses (Tables 6). original research report periority of one regimen over the other. Chemotherapy alone with radiation has also been reported in prospective phase II trials. Use of highldose methotrexate (8 g/m 2 ) with leucovorin rescue followed by maintenance methol l trexate without radiation therapy, reported a median OS of 23% in 23 evaluable patients. 12 Similarly a 3 year EFS of 35% has been reported in a randomized phase II trial of high dose methotrexate ± high dose cytosine arabil l noside. 28 A SWOG/RTOG trial of 102 patients with a lower dose of methotrexate followed by WBRT reported a median OS of 36.9 months (60 and 21.8 months, rel l spectively, for those younger and older than 60 years of age). 15 A 5lyear OS of 77% has been reported with use of highldose chemotherapy and stem cell transplantation without RT in a single arm phase II trial. 29 Our analysis failed to show a prognostic impact for any factors except age and primary therapy (CMT vs. RT alone) in univariate analysis while on multivariate analysis, age alone appeared to be the prognostic factor. We did not have enough data to analyze the impact of other prognostic factors reported by IESLG (LD, bone marrow involvement and CSF cytology).
In conclusion, our data support the previously rel l ported retrospective data and prospective phase II data of superiority of combined modality therapy with chel l motherapy and radiation compared to either one alone with age alone being the significant factor impacting prognosis in our study. Combined chemoradiotherapy should therefore be the treatment of choice for newly diagnosed primary CNS lymphoma until randomized trials provide data to the contrary.
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